Thursday, May 1, 2025

No Result

View All Result

Media

Support Us

No Result

View All Result

Health

Life on hold – How Canada’s drug approval delays endanger patients: Nigel S.B. Rawson and John Adams

March 13, 2025

Nigel Rawson

Columns

On this rarest of days, commit to support those with rare diseases: John Adams, Beth Vanstone and Nigel Rawson in the Financial Post

February 29, 2024

Past Events

Delayed and denied: The challenges faced by Canadians with rare disorders

January 16, 2024

Columns

Spend less on dental care and pharmacare, more on treatments for rare medical disorders: Nigel Rawson and John Adams in the Financial Post

January 4, 2024

When suicide attempts turn into assisted suicides: Alexander Raikin for Inside Policy

Columns

Government hostility to biopharmaceutical industry reduces access to innovative drugs: Nigel Rawson and John Adams in the Hill Times

November 16, 2023

Columns

Pharmacare won’t help Canadians with rare disorders: Nigel Rawson and John Adams in the Financial Post

November 7, 2023

Columns

Americans look to Canada for lower drug prices, but are they getting the full picture?: Nigel Rawson and John Adams in The Hill

October 7, 2023

Commentary

Waiting for new drugs for rare disorders in Canada

September 6, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

August 30, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

August 23, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

August 16, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

August 9, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

August 2, 2023

Page 2 of 4 Prev 1 2 3 4 Next

Newsletter Signup

Email Address *

First Name *

Last Name *

*Required Fields

Follow us on

Macdonald-Laurier Institute

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

No Result

View All Result

Life on hold – How Canada’s drug approval delays endanger patients: Nigel S.B. Rawson and John Adams

Nigel Rawson

On this rarest of days, commit to support those with rare diseases: John Adams, Beth Vanstone and Nigel Rawson in the Financial Post

Delayed and denied: The challenges faced by Canadians with rare disorders

Spend less on dental care and pharmacare, more on treatments for rare medical disorders: Nigel Rawson and John Adams in the Financial Post

Government hostility to biopharmaceutical industry reduces access to innovative drugs: Nigel Rawson and John Adams in the Hill Times

Pharmacare won’t help Canadians with rare disorders: Nigel Rawson and John Adams in the Financial Post

Americans look to Canada for lower drug prices, but are they getting the full picture?: Nigel Rawson and John Adams in The Hill

Waiting for new drugs for rare disorders in Canada

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

Top News

How provincial trade barriers rip off Canadians: Peter Copeland & Ryan Manucha for Inside Policy Talks

‘One China’ second thoughts: Why Canada must support Taiwan’s resilience

Singh, Carney help perpetuate lie that Israel’s committing ‘genocide’: Brian Cox in the National Post

Multimedia

Interfaith Dialogue, the Road to Peace, and Israel’s Future: Loay Alshareef in conversation with Casey Babb

Can the CBC survive without government subsidies? Peter Copeland and Peter Menzies for Inside Policy Talks

Between Shadow and Sunrise – Palestine’s Unwritten Future: Casey Babb and Ahmed Alkhatib for the Promised Land Podcast

Rushing to death in Canada’s MAiD regime: Ramona Coelho for Inside Policy

Canada’s conservatives care about freedom—except in health care: Shawn Whatley in the Hub

Poilievre has been vindicated for refusing security clearance: Ryan Alford in the National Post

Why are Western Canadian oil prices so strong?: Rory Johnston for Inside Policy

How Poilievre can improve healthcare in Canada: Shawn Whatley in Troy Media

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us